Navigation Links
Haemonetics Reports 8% Revenue Growth for Second Quarter of Fiscal 2012, Adjusted Earnings Per Share of $0.72 and Updates Previously Provided Full Year Earnings Guidance
Date:10/31/2011

,339$ 78,7409.7%International

93,10688,0935.7%Net revenues

179,445166,8337.6%Disposable revenuesPlasma disposables

64,40856,51414.0%Blood bank disposablesPlatelet

42,19539,7466.2%Red cell

11,64511,2943.1%53,84051,0405.5%Hospital disposablesSurgical

16,20616,0111.2%OrthoPAT

7,2958,281(11.9%)Diagnostics

5,6594,64721.8%29,16028,9390.8%Subtotal

147,408136,4938.0%Software solutions

17,19916,1256.7%Equipment & other

14,83814,2154.4%Net revenues

$ 179,445$ 166,8337.6%Six Months Ended10/1/2011
As Reported10/2/2010
As Reported% Inc/(Dec) vs
Prior YearRevenues by geographyUnited States

$ 172,734$ 158,0499.3%International

177,280171,8233.2%Net revenues

350,014329,8726.1%Disposable revenuesPlasma disposables

127,168112,43113.1%Blood bank disposablesPlatelet

79,50476,0634.5%Red cell

23,51422,6084.0%103,01898,6714.4%Hospital disposablesSurgical

31,94832,362(1.3%)OrthoPAT

15,04917,238(12.7%)Diagnostics

11,2739,35520.5%58,27058,955(1.2%)Subtotal

288,456270,0576.8%Software solutions

35,35932,5858.5%Equipment & other

26,19927,230(3.8%)Net revenues

$ 350,014$ 329,8726.1%Consolidated Balance SheetsPeriod ending10/1/20114/2/2011AssetsCash and cash equivalents

$183,421$196,707Accounts receivable, net

129,242127,166Inventories, net

101,44484,387Other current assets

26,99340,571Total current assets

441,100448,831Net PP&E

156,866155,528Other assets

225,756228,905   Total assets

$823,722$833,264Period ending10/1/114/2/11Liabilities & Stockholders' EquityShort term debt & current maturities

$3,080$ 
'/>"/>

SOURCE Haemonetics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Haemonetics Sets Date for Second Quarter Fiscal Year 2012 Earnings Release: October 31, 2011
2. Haemonetics Sets Date for Fourth Quarter Fiscal Year 2011 Earnings Release: May 2, 2011
3. Haemonetics to Present at J.P. Morgan Healthcare Conference
4. Fenwal Responds to New Lawsuit From Haemonetics; Reiterates Commitment to Blood Centers
5. Pacira Pharmaceuticals, Inc. Reports Third Quarter 2011 Financial Results
6. ReportsnReports - Hyper Acute Pancreas (Pancreatic Cancer) - Analysis and Forecasts to 2020
7. HeartWare International Reports Third Quarter 2011 Revenues of $21.3 Million; 54% Increase From $13.8 Million in Third Quarter 2010
8. Uroplasty Reports Fiscal Second Quarter 2012 Financial Results
9. Varian Medical Systems Reports Results for Fourth Quarter of Fiscal Year 2011
10. ERT Reports Third Quarter 2011 Operating Results
11. CryoLife Reports Financial Results for the Third Quarter and First Nine Months of 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, said today ... Global Healthcare Conference on Wednesday, September 10. ... Officer, will provide an update on the company, beginning ... Daylight Time).   A webcast of the ...
(Date:8/29/2014)... 2014 Research and Markets  has announced the ... 2014" report to their offering. The ... of the largest segments of pharmaceuticals industry. The numbers of ... available therapies were unable to meet the market requirements. There ... CNS disorder, especially over the past two decades. The market ...
(Date:8/29/2014)... , Aug. 29, 2014  United Therapeutics Corporation ... U.S. District Court for the District of ... in the company,s case against Sandoz, Inc. regarding United ... Peter Sheridan ruled that U.S. Patent No. 6,765,117 ... enjoined Sandoz from marketing its generic product until the ...
Breaking Medicine Technology:US CNS Disorders Drug Pipeline Insight 2014 2District Court Decision Received In Remodulin Patent Case 2
... A report released,today by The Cornucopia Institute ... formula are seriously endangering the health of,some formula-fed ... Human Breast Milk in the,Laboratory, details research questioning ... produced in laboratories and extracted from,algae and fungus, ...
... on study results demonstrating survival advantage ... months when added to standard therapy, -- First study ... BOULDER, Colo., Jan. 24 Pharmion Corporation,(Nasdaq: PHRM ) ... positive opinion to recommend approval of Thalidomide,Pharmion(R) for use in ...
Cached Medicine Technology:Infant Formula Manufacturers Again under Ethical Cloud: 'Marketing Gimmick' Linked to Serious Illnesses 2Infant Formula Manufacturers Again under Ethical Cloud: 'Marketing Gimmick' Linked to Serious Illnesses 3Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 2Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 3Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 4Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 5Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 6
(Date:9/1/2014)... New York (PRWEB) September 01, 2014 ... store, retrieve, organize and analyze biological and genetic ... of the activity of developing software tools to ... not to be confused with biological computation. While ... better understanding of biology can its related concepts, ...
(Date:9/1/2014)... Parties involved in federally-filed Tylenol lawsuits ( http://www.tylenollawsuitclaims.com/ ) ... September, where issues related to claims involving the pain ... Pennsylvania, Bernstein Liebhard LLP reports. , According to ... website, the meeting is scheduled to take place on ... latest of several Tylenol conferences that have taken place ...
(Date:9/1/2014)... Top10BestSEOHosting.com has recently compared many ... suppliers carefully, Top10BestSEOHosting.com is here to announce that ... hosting suppliers in 2014. , JustHost ( http://www.justhost.com/track/seohosts ... top-of-the-line shared hosting plan. The company’s approach to ... is affordable, accessible and powerful enough for anyone ...
(Date:9/1/2014)... Daily Gossip reveals in it's review on ... gives members access to thousands of professionally designed tattoo ... aims to help both people who plan on getting ... looking for inspiration in creating one of a kind ... by visiting the official website at: http://www.dailygossip.org/atattoo-me-now-6444 . ...
(Date:9/1/2014)... CA (PRWEB) September 01, 2014 AttorneyOne.com, ... regarding all the latest information from the FDA on ... The US FDA announced on August 28, that specific ... recalled (Class I) as the device may reverse ... DePuy Synthes Craniomaxillofacial (CMF) Distraction System is an implant ...
Breaking Medicine News(10 mins):Health News:Bioinformatics Market: A fusion of Computers and Biological Data 2Health News:Bioinformatics Market: A fusion of Computers and Biological Data 3Health News:Bioinformatics Market: A fusion of Computers and Biological Data 4Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Why Top10BestSEOHosting.com Calls Them Great Web Hosting Suppliers 2Health News:Tattoo Me Now Review Reveals Unique Ideas for Tattoo Designs 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 2Health News:DePuy Synthes Craniomaxillofacial Distraction System Recalled (Class I): AttorneyOne Monitors and Keeps Consumers Informed 3
... but not frequency, study suggests , , THURSDAY, April ... 2-year-olds relate to each other affects the quality -- ... "terrible twos." And a child,s temperament plays a role ... to a new study. , Interactions between 60 mothers ...
... 3, 2008 With spring here and,summer fast approaching, ... said, attractive feet are a MUST!, YogaToes(R) are ... feel great. YogaToes(R) beautify feet with passive exercise that,helps ... by tight,shoes, high heels and overexertion., "Women aren,t ...
... MedQuist,Inc. (Pink Sheets: MEDQ.PK) announces that ... hospital in Newburyport, Mass., has selected MedQuist,Technology ... solution,including dictation, transcription and speech recognition. Anna ... and is home to a,nationally recognized Wound ...
... Third Bank,today announced a strategic alliance with GHN-Online ... cycle management services to,the healthcare industry, that will ... healthcare providers. The alliance,will enable Fifth Third Bank ... to payments -- and integrate the data into ...
... Expands Global Product Potential, LEXINGTON, Mass., April ... ) today announced the signing of a,License, Supply ... rights to market VANTAS(R) (histrelin acetate subcutaneous,implant) throughout ... is a,12-month implant for the treatment of advanced ...
... a child for a lifetime, researchers say, , , THURSDAY, April ... United States were victims of maltreatment in 2006 during their ... or neglect during their first week of life, federal officials ... examination of the risk for nonfatal maltreatment of children less ...
Cached Medicine News:Health News:Mother-Child Bond Affects Quality of Conflict Resolution 2Health News:New Ten-Minute Foot Exercisers Beautify Feet for Spring and Summer Sandal Season 2Health News:MedQuist Technology Solutions to Power Documentation Workflow at New England Facility 2Health News:MedQuist Technology Solutions to Power Documentation Workflow at New England Facility 3Health News:Fifth Third Bank Teams with Leading Healthcare Providers to Deliver a Claims-to-Payment Business Intelligence Platform 2Health News:Fifth Third Bank Teams with Leading Healthcare Providers to Deliver a Claims-to-Payment Business Intelligence Platform 3Health News:Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation 2Health News:Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation 3Health News:Indevus Pharmaceuticals Licenses European Rights for VANTAS(R) to Orion Corporation 4Health News:More Than 90,000 U.S. Infants Are Victims of Abuse or Neglect 2Health News:More Than 90,000 U.S. Infants Are Victims of Abuse or Neglect 3
2.5mm...
... 12 bevel tip; silicone sleeve ... is opposite curve, Designed for ... Sleeve acts as stop & ... chance of trauma to the ...
Stab incision blades color coded for simple and accurate identification...
Formed 12.0mm from bend to tip; radius is 12.5 mm;, Curved sharp cutting edge requires less pressure to cut the capsule, reducing stress to zonules. 1.5mm long x .75 mm wide...
Medicine Products: